FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Binder Gwendolyn						2. Issuer Name and Ticker or Trading Symbol Instil Bio, Inc. [TIL]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last)	,		Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/14/2023								Officer below)	(give title		Other (s below)	pecify
C/O INSTIL BIO, INC. 3963 MAPLE AVENUE, SUITE 350					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person				
(Street) DALLAS TX 75219					I										iled by More than One Reporting			
(City) (State) (Zip)				- Ru	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - Nor	n-Deriv	vative	Sec	curitie	s Ac	quired, D	isp	osed c	of, or Be	neficial	ly Owne	t			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						Execution Date,			Code (In:	Transaction Disposed O Code (Instr. 5)		ties Acquired (A) or d Of (D) (Instr. 3, 4 a		Benefic	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct c r Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	<i>'</i>	Amount	(A) or (D)		Transac (Instr. 3	ction(s)		(
		T							uired, Dis s, options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transactio Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Ex ₁	piration te	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$11.18	06/14/2023			A		1,500		(1)	06/	/13/2033	Common Stock	1,500	\$0	1,500		D	

Explanation of Responses:

1. The option will vest in 12 equal monthly installments commencing on July 14, 2023, subject to the Report Person's continued service as a director through the vesting date.

Remarks:

/s/ Sandeep Laumas, M.D. Attorney-in-Fact for

** Signature of Reporting Person

Gwendolyn Binder

01/10/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.